Abstract #2243
MRS changes in diffuse intrinsic pontine gliomas correlate with survival
Stefan Bluml 1,2 and Ashok Panigrahy 3
1
Children's Hospital Los Angeles/USC, Los
Angeles, CA, United States,
2
Rudi
Schulte Research Institute, Santa Barbara, CA, United
States,
3
Children's
Hospital of Pittsburgh/UPMC, Pittsburgh, PA, United
States
Diffuse intrinsic pontine glioma (DIPG) carry the worst
prognosis in pediatric neurooncology, with the majority
of patients dying within six to 18 months after
diagnosis. Due to the lack of tissue samples, small
patient numbers, and the challenges of clinical research
in the pediatric population, there has been no
improvement in outcomes for decades. This study
demonstrates that serial MRS identifies subgroups of
longer survival vs. shorter survival survival at an
early stage of the disease. This finding demonstrates
that MRS could be used to adjust therapies in individual
patients but also to evaluate the effectiveness of new
treatment strategies in a timely fashion.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
